Northern Trust’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
Other funds holding LYEL
AVM
GP
FCMI
OPL
VCM
DC
AC
FCMV
Northern Trust's LYEL Position: Q1 2026 in Review
Northern Trust held its Lyell Immunopharma (LYEL) position steady in Q1 2026 at 30,280 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #3537.
Northern Trust first reported a position in LYEL in Q3 2021 and has held it in 19 quarters since. The position peaked at $14.9M in Q3 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.
- Northern Trust held 30,280 shares of Lyell Immunopharma worth $607K as of Q1 2026.
- Northern Trust left its Lyell Immunopharma share count unchanged in Q1 2026.
- Lyell Immunopharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3537 holding.
- Northern Trust first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 19 quarters since.
- Northern Trust's Lyell Immunopharma position peaked at $14.9M in Q3 2022.
- 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.